

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE:

In re Application of:

Kasid et al.

Application No. 10/075,994

Filed: February 15, 2002

For: CHEMOSI

CHEMOSENSITIZING WITH LIPOSOMES CONTAINING OLIGONUCLEOTIDES Group Art Unit: 1615

Examiner: Unassigned

INFORMATION DISCLOSURE STATEMENT

Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date

In re Appln. of Kasid et al. Application No. 10/075,994

		rst Office Action on the merits; or (d) before the mailing of a first Office Action ne filing of a request for continued examination under 37 CFR 1.114.
	37 CF	(a), (b), (c) or (d) above, but before the mailing date of a final action under R 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that vise closes prosecution in the application, and includes <i>one</i> of:
		the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).
	\bigcap^{or}	the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).
	under and or 37 CF	the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance 37 CFR 1.311, or an action that otherwise closes prosecution in the application, nor before payment of the issue fee, and includes the Statement under R 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as the in 37 CFR 1.17(p) (see "Fees" below).
	payme contain 37 CF \$180 a NOTE: May 29	he mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before nt of the issue fee, and within thirty days of receiving each item of information ned in the Information Disclosure Statement, and includes the Statement under R 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of its set forth in 37 CFR 1.17(p) (see "Fees" below). This is for original applications except applications for a design patent, filed on or after 2000, wherein a paper containing only an Information Disclosure Statement in compliance CFR 1.97 and 1.98 is being filed.
Copie	s of the	References
	Attach relevar an Eng action degree	s of the references listed on the enclosed Form 1449 are enclosed herewith, ed to each reference not in the English language is a concise explanation of the nce pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or glish-language abstract, or an English-language version of the search report or by a foreign patent office in a counterpart foreign application indicating the of relevance found by the foreign office is being submitted in lieu of a concise ation of the relevance pursuant to 37 CFR 1.98(a)(3).
	А сору	y of the foreign search report is enclosed herewith.
	parent furnish submit The E accord Proced relied	ferences listed on the enclosed Form 1449 were previously identified in the application(s) of the present application, and copies of the references were ted at that time. Accordingly, additional copies of the references are not ted herewith, so as not to burden the file with duplicate copies of references. Examiner is respectfully requested to carefully review the references in ance with the requirements set out in the Manual of Patent Examining ture. In accordance with 37 CFR 1.98(d), the details of the parent application(s) upon for an earlier filing date under 35 USC 120 in which copies of the nees were previously furnished are set out below:

In re Appln. of Kasid et al. Application No. 10/075,994

U.S. APPLICATIONS Status (check one)								
	S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED			
1.								
2. 3.								
<u>J.</u>	<u>.</u>	<u> </u>			<u>. </u>			
State	ment under 37 CFR	1.97(e)						
	Information Discler foreign patent office	hereby states that each sure Statement was finction in a counterpart foreing the Information	rst cited in a gn patent appl	ny commun ication not r	ication from a			
	Information Disclosoffice in a counte undersigned after m Information Disclosoffice.	hereby states that no sure Statement was cited rpart foreign patent ap naking reasonable inquir osure Statement was love than three months ont.	l in a communi pplication, and ry, no item of i known to any	cation from to the known to the	a foreign patent owledge of the contained in the designated in			
State	ment under 37 CFR	1.704(d)						
	The undersigned hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.							
Fees		t-						
	No fee is owed by the IDS Fee of \$18	ne applicant(s). 0 under 37 CFR 1.17(p)	is enclosed he	rewith.	(c)			
Metho	od of Payment of Fed	es						
	Attached is a check in the amount of \$ Charge Deposit Account No. 12-1216 in the amount of \$ this communication is enclosed for that purpose.) (A duplicate copy of							
Autho	orization to Charge	Additional Fees						
⊠ .	If any additional fee Deposit Account No for that purpose.)	es are owed in connection in the connection in t	on with this content copy of this	mmunication communicat	, please charge ion is enclosed			

In re Appln. of Kasid et al. Application No. 10/075,994

Instructions as to Overpayment

Credit Account No. 12-1216.

M. Daniel Hefner, Reg. No. 41,826 LEYDIG, VOIT & MAYER, LTD. Two Prudential Plaza, Suite 4900 180 North Stetson Chicago, Illinois 60601-6780 (312) 616-5600 (telephone) (312) 616-5700 (facsimile)

Date: September 11, 2003 IDS (Revised 5/21/03)

	S. J.					
SEP 1 5 2003	y-J				Complete if Known	
Substitute for fo	rm, 1449A/B/PTO			Application Number	10/075,994	7)
L INIE	MATION	DISC	OSLIDE	Filing Date	February 15, 2002	
RADEMA	RMATION TEMENT B		DUSONE	First Named Inventor	Kasid et al.	(C). (S)
SIA	IEMENIB	YAP	PLICANI	Group Art Unit	Unassigned	Ch 1
•	(Use as many shee	ts as nec	essary)	Examiner Name	Unassigned	1, 6,
Sheet	2	of	2	Attorney Docket Number	219604	19 Os
-		•				6,

			'90	
		OTHER - NON PATENT LITERATURE DOCUMENTS	9	2
-	D	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	Trans	Hation
Examiner Initials	Doc. No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*+
	AR	GOKHALE et al., "Antisense raf oligodeoxyribonucleotide is protected by liposomal		
		encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for		ŀ
		gene therapy of radioresistant cancer," Gene Therapy, 4, 1289-1299 (1997)		
	AS	GOKHALE et al., "Antisense raf Oligodeoxyribonucleotide Is a Radiosensitizer In Vivo,"		
		Antisense & Nucleic Acid Drug Development, 9, 191-201 (1999)		
	AT	JAMES, "Towards gene-inhibition therapy: a review of progress and prospects in the		
*	7 '	field of antiviral antisense nucleic acids and ribozymes," Antiviral Chem. & Chemoth., 2,	<u>:</u> :	
·		191-214 (1991)	000	
	A U	KASID et al., "Effect of Antisense c-raf-1 on Tumorigenicity and Radiation Sensitivity of a Human Squamous Carcinoma," Science, 243, 1354-1356 (1989)		
	AV	LAPPALAINEN et al., "Comparison of Cell Proliferation and Toxicity Assays Using Two		
· .		Cationic Liposomes," Pharmaceutical Research, 11(8), 1127-1131 (1994)		
	AW	LITIZINGER et al., "Fate of cationic liposomes and their complex with oligonucleotide in vivo," <i>Biochimica et Biophisica Acta</i> , 1281, 139-149 (1996)		
• •	AX	MAHER et al., "Specific Hybridization Arrest of Dihydrofolate Reductase mRNA in Vitro		
	^^	Using Anti-sense RNA or Anti-sense Oligonucleotides," Archives of Biochemistry and		
			·	l
	A \/	Biophysics, 253, 214-220 (1987)		
	AY	MILNER et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays," <i>Nature Biotechnology</i> , 15, 537-541 (1997)		
	AZ	PATEL et al., "Nucleotide Sequence Analysis of c-raf-1 cDNA and Promoter From a		
	–	Radiation-Resistant Human Squamous Carcinoma Cell Line: Deletion Within Exon 17,"		
		Molecular Carcinogenesis, 8, 7-12 (1993)		
	ВА	SCHOFIELD et al., "Non-viral approaches to gene therapy," <i>Brit. Med. Bull.</i> , 51, 56-71		٠.,
- (-		(1995)		
	ВВ	SEUNG et al., "Genetic Radiotherapy Overcomes Tumor Resistance to Cytotoxic	-	
	ьь	Agent," Cancer Research, 55, 5561-5565 (1995)		٠.,
	D 0 :			
7	BC.	SOLDAATENKOV et al., "Inhibition of Raf-1 Protein Kinase by Antisense		
	-	Phosphorothioate Oligodeoxyribonucleotide Is Associated with Sensitization of Human		
• .		Laryngeal Squamous Carcinoma Cells to Gamma Radiation," Cancer J. Sci. Am., 3, 13-		
		20 (1997)		
.: .	BD-	VERMA et al., "Gene therapy – promises, problems and prospects," <i>Nature</i> , 389, 239-		
		242 (1997)		
8				
		*		
<i>a</i>				
•	-t			
				
	<u> </u>			
· .				
	•			

Examiner Signature		Date Considered	
	<u> </u>		

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

crn 1 5	s sign () inside this box	→ [-	E			
H JLI	rm 1449A/B/PTO				Complete if Known	
Sepstitute for fo	m 1469A/B/PTO			Application Number	10/075,994	$\overline{\lambda}$
TAMES	MATION I	חופר	I OSLIDE	Filing Date	February 15, 2002	-
				First Named Inventor	Kasid et al.	1/2
SIA	TEMENT BY	r AP	PLICANI	Group Art Unit	1615	<u> </u>
	(Use as many sheet	's as ned	cessary)	Examiner Name	Unassigned	Z, <
Sheet	1	of	2 ,	Attorney Docket Number	219604	

	U.S. PATENT DOCUMENTS							
		U.S. Patent Document				300		
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate		
	AA	5,283,185		Epand et al.	Feb. 1, 1994			
	AB	5,641,662		Debs et al.	June 24, 1997			
	AC	5,696,277		Hostetler et al.	Dec. 9, 1997			
***	AD	5,756,122		Thierry et al.	May 26, 1998			
	AE	5,827,703		Debs et al.	Oct. 27, 1998			
	AF	5,952,229		Monia et al.	Sep. 14, 1999			
	AG	6,120,798		Allen et al.	Sep. 19, 2000			
	АН	6,126,965		Kasid et al.	Oct. 3, 2000			
	Al	6,248,351	B1	Xing et al.	June 19, 2001			
•	ΑJ	6,333,314	B1	Kasid et al.	Dec. 25, 2001			
-	<u> </u>							
	<u> </u>							
			 	· · · · · · · · · · · · · · · · · · ·				

				FORE	IGN PATENT DOCUMENTS			
		Foreign Patent Document				1	Translation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+
	AK	wo	95/11670		THE LIPOSOME COMPANY, INC.	May 4, 1995		
	AL	wo	95/32987		MACEUTICALS, INC.	Dec. 7, 1995		
		ļ		1				ļ
				_				
				 				
			 	 -				
				 		<u> </u>		
			L	J	l			

OTHER - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Doc. No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher,		Trans Yes	lation No*+		
	АМ	city and/or country where published. BRANCH, "A Good Antisense Molecule is Hard to Find," TIBS, 23, 45-50 (1998)				
	AN	CROOKE, "Antisense Research and Application," Springer-Verlag, 1, 1-50 (1998)				
	AO	CRYSTAL, "Transfer of Genes to Humans: Early Lessons and Obstacles to Success," Science, 270, 404-410 (1995)				
	AP	FRIEDMANN, "Overcoming the Obstacles to Gene Therapy," Science America, June, 96-101 (1997)	*			
	AQ	GOKHALE et al., "Enhanced inhibition of Raf-1 kinase by liposomal antisense raf oligodeoxyribonucleotide in human squamous carcinoma cells," American Asso. Cancer Research, 37, Poster Section 6 #2807 (1996)				

Examiner Signature	Date Considered

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).